Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP), the biopharma company, has unveiled the pre-clinical results of TNX-801, its live virus horsepox vaccine that prevents smallpox and monkeypox, in a poster at the 2020 ASM Biothreats Conference held from January 28 to the 30th in Arlington, Virginia.

The poster, which was entitled “Synthetic Chimeric Horsepox Virus (scHPXV) Vaccination Protects Macaques from Monkeypox”, showcases the analysis of TNX-801 and offers proof that it works.

A number of Cynomolgus Macaque, a type of monkey indigenous to Southeast Asia, were vaccinated with either high-dose or low-dose TNX-801. The poster presentation reveals that eight of eight animals vaccinated with TNX-801 were successfully immunized from intra-tracheal monkeypox. Two of three monkeys vaccinated with TNX-1200, meanwhile, another Tonix smallpox vaccine, and all animals who received the control, developed monkey pox lesions.

“[Two] of three evaluable animals vaccinated with TNX-1200, and all animals who received the vehicle control, developed monkeypox lesions after challenge,” according to Tonix. “In addition, after a single vaccination, four of four animals vaccinated with a high dose of TNX-801 and three of four animals vaccinated with a low dose of TNX-801 responded with a cutaneous reaction called a “take” that is a biomarker of protective immunity in campaigns to control smallpox contagion.”

Tonix is developing an array of pharmaceutical products that take aim at neuropsychiatric conditions.

Its chief treatment is Tonmya (TNX-102SL), which contains 2.8 mg of cyclobenzaprine HCl and treats post-traumatic stress disorder (PTSD) as well as fibromyalgia and agitation in Alzheimer’s disease, plus alcohol use disorders, and is in Phase 3 trials. Drilling into the details, Tonmya has proved successful in improving the quality of sleep for patients with PTSD as well as those with fibromyalgia, which triggers musculoskeletal pain and fatigue.